Notizie AIOM – anno XV
FDA Grants Priority Review to Durvalumab for Locally Advanced Unresectable NSCLC
October 17, 2017 - The FDA has granted a priority review to a supplemental biologics license application (sBLA) for durvalumab for the treatment of patients with stage III, unresectable non–small cell lung cancer (NSCLC), based on positive progression-free survival ...Leggi tutto
FDA Grants Olaparib Priority Review in BRCA+ Breast Cancer
October 18, 2017 - The FDA has granted a priority review to a supplemental New Drug Application (sNDA) for olaparib for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy in the neoadjuvant, ...Leggi tutto
Web-app
Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore del pancreas è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due versioni, ...Leggi tutto
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies in previously treated patients with advanced squamous (CheckMate 017; ClinicalTrials.gov identifier: NCT01642004) or nonsquamous (CheckMate ...Leggi tutto
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
If not promptly recognized, endocrine dysfunction can be life threatening. The incidence and risk of developing such adverse events (AEs) following the use of immune checkpoint inhibitor (ICI) regimens are unknown. To compare the incidence and risk of endocrine AEs following ...Leggi tutto
Revised Guidelines Helping to Advance Kidney Cancer Care
October 13, 2017 - Management of patients with localized kidney cancer became a more uniformed, guided, and evidence-based approach earlier this year with revised guidelines individually developed by the American Society of Clinical Oncology (ASCO), American Urological Association ...Leggi tutto
Frontline Alectinib Recommended for EU Approval for ALK+ NSCLC
October 13, 2017 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of alectinib for the first-line treatment of adults with ALK-positive, advanced non–small cell lung cancer (NSCLC). Based on phase ...Leggi tutto